Effect of Symbicort on HAT and HDAC in Sputum Macrophages of COPD

A Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Effect of Symbicort® and Pulmicort® on HAT and HDAC Expression and Activity in Induced Sputum Cells Obtained From COPD Patients.

The purpose of the study is to compare histone acetyltransferase (HAT) and histone deacetylase (HDAC) expressions and activities in induced sputum macrophages obtained from patients with moderate to severe COPD and age-matched normal non-smokers

Study Overview

• Status: Withdrawn
• Conditions: Chronic Obstructive Pulmonary Disease (COPD); Age Matched Healthy Volunteers (Non-smokers)
• Intervention / Treatment: Procedure: Skin Prick Test; Procedure: Impulse Oscillometry; Procedure: Exhaled Nitric Oxide; Procedure: Spirometry; Procedure: Reversibility; Procedure: Exhaled Breath Condensate; Procedure: Sputum Induction

• Study Type: Interventional
• Phase: Phase 4

Contacts and Locations

Study Locations

• United Kingdom
  • London, United Kingdom, SW3 6LY
    • Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Inclusion Criteria-Healthy non-smokers

• Non-smoking volunteer
• aged 40 -75 years (age matched to COPD patients)
• Normal spirometry (normal FEV1/FVC ratio >70% and FEV1>80% predicted)
• Subjects are able to give informed consent

Inclusion Criteria-COPD patients (stage II-III according to the GOLD guidelines)

• Current and/or ex-smokers with no less than 10 pack-year smoking history
• aged 40 -75 years
• FEV1 greater than or equal to 30% and less than 80% of predicted (the upper value is a prostbronchodilator value)
• FEV1/FVC < 70%
• Patients with stable COPD
• Inhaled Corticosteroid (ICS) treatment, if exists, must be stopped for 2 weeks prior the study treatment
• Long-acting beta2-agonists and theophylline need to be stopped at least 3 days before run-in , but anti-cholinergics will be allowed throughout the study
• The subjects are able to give informed consent

Exclusion Criteria:

Exclusion Criteria-Healthy non-smokers

• Pregnancy, breast-feeding or planned pregnancy during the study. Fertile women not using acceptable contraceptive measures, as judged by the investigator
• Upper respiratory infection within the last 4 weeks
• Subjects who have received research medication within the previous one month
• Subjects unable to give informed consent
• Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study.

Exclusion Criteria-COPD patients

• Evidence of asthma
• Bronchodilator reversibility > 12%
• Pregnancy, breast-feeding or planned pregnancy during the study. Fertile women not using acceptable contraceptive measures, as judged by the investigator
• Patients who have had oral steroids within 8 weeks prior to the screening visit.
• Patients who are already on ICS and in which it is considered unsafe (as judged by the Investigator) to stop this treatment for the study period.
• Patients who have had an exacerbation which required treatment with oral steroids during the last 2 months prior to the screening visit.
• Upper respiratory infection within the last 4 weeks
• Subjects who have received research medication within the previous one month
• Subjects unable to give informed consent
• Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study
• Patients with significant co-morbidities as judged by the investigator
• Any other respiratory disease, which is considered by the investigator to be clinically significant

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

What is the study measuring?

Primary Outcome Measures

Outcome Measure
HDAC and HAT activity ratio

Secondary Outcome Measures

Outcome Measure
Several inflammation and anti-inflammation markers and lung function will be evaluted as shown below.

Collaborators and Investigators

• Sponsor: Imperial College London
• Collaborators: AstraZeneca
• Investigators: Principal Investigator: Peter J Barnes, MA DM DSc FRCP, Imperial College London; Principal Investigator: Kazuhiro Ito, PhD, Imperial College London; Principal Investigator: ian adcock, PhD, Imperial College London; Principal Investigator: Sergei A Kharitonov, MD PhD, Imperial College London

Study record dates

Study Major Dates

• Study Start: April 1, 2006
• Primary Completion (Actual): June 1, 2007
• Study Completion (Actual): June 1, 2007

Study Registration Dates

• First Submitted: February 13, 2006
• First Submitted That Met QC Criteria: February 13, 2006
• First Posted (Estimate): February 14, 2006

Study Record Updates

• Last Update Posted (Actual): August 7, 2019
• Last Update Submitted That Met QC Criteria: August 5, 2019
• Last Verified: August 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Lung Diseases; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Vasodilator Agents; Autonomic Agents; Peripheral Nervous System Agents; Protective Agents; Bronchodilator Agents; Anti-Asthmatic Agents; Respiratory System Agents; Antioxidants; Free Radical Scavengers; Endothelium-Dependent Relaxing Factors; Gasotransmitters; Nitric Oxide
• Other Study ID Numbers: 05/Q0403/171; EudraCT Number: 2005-003297-13